Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat lub starsi
- •Potwierdzony nowotwór gruczołu krokowego (rak prostaty)
- •Rak prostaty, który rozprzestrzeniał się na inne części ciała i nie reaguje na leczenie hormonalne
- •Poprzednie leczenie co najmniej jednym lekiem hormonalnym i co najmniej jednym chemioterapią
- •Prawidłowe funkcjonowanie narządów wewnętrznych (nerek, wątroby, serca)
✗ Disqualifies
- •Wcześniejszy przeszczep solidnego narządu
- •Wcześniejsze leczenie terapią CAR-T lub innymi nowoczesными biológicznych lekami skierowanymi na PSMA
- •Poważne choroby serca lub naczyń krwionośnych
- •Wcześniejsze leczenie radioaktywnymi lekami lub innymi terapiami skierowanymi na PSMA
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- August 13, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (36)
University of Alabama at Birmingham Hospital
Birmingham, United States
Mayo Clinic
Phoenix, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
UCLA Department of Medicine
Los Angeles, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, United States
Yale New Haven Hospital
New Haven, United States
Mayo Clinic
Jacksonville, United States
University of Chicago Medical Center
Chicago, United States
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, United States
University of Minnesota Medical Center
Minneapolis, United States
Mayo Clinic
Rochester, United States
Washington University School of Medicine
St Louis, United States
Northwell Health R.J. Zuckerberg Cancer Hospital
Lake Success, United States
NYU Langone Health Long Island
Mineola, United States
NYU Langone Health
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Weill Cornell Medicine
New York, United States
Montefiore Medical Center
The Bronx, United States
University of Cincinnati Medical Center
Cincinnati, United States
The Ohio State University
Columbus, United States
Penn State Milton S. Hershey Medical Center
Hershey, United States
Thomas Jefferson University Honickman Center
Philadelphia, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Rhode Island Hospital
Providence, United States
Medical University of South Carolina
Charleston, United States
Sarah Cannon Research
Nashville, United States
Mary Crowley Cancer Research
Dallas, United States
University of Texas Southwestern Medical Center
Dallas, United States
Houston Methodist Hospital
Houston, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, United States
Chris O'Brien Lifehouse (COBLH)
Camperdown, Australia
Southern Oncology Clinical Research Unit (SoCRU)
Bedford Park, Australia
Linear Clinical Research Ltd.
Nedlands, Australia
Trial contact
Janux Therapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.